Blood Research

Cited by CrossRef (16)

  1. Bani Bandana Ganguly, N.N. Kadam. Mutations of myelodysplastic syndromes (MDS): An update. Mutation Research/Reviews in Mutation Research 2016;769:47
    https://doi.org/10.1016/j.mrrev.2016.04.009
  2. Bani Bandana Ganguly, Debasis Banerjee, Mohan B. Agarwal. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. Blood Cells, Molecules, and Diseases 2018;69:90
    https://doi.org/10.1016/j.bcmd.2017.10.001
  3. Sotirios G. Papageorgiou, Diamantina Vasilatou, Christos K. Kontos, Ioannis Kotsianidis, Argiris Symeonidis, Athanasios G. Galanopoulos, Eleftheria Hatzimichael, Aekaterini Megalakaki, Elias Poulakidas, Panagiotis Diamantopoulos, Theodoros P. Vassilakopoulos, Panagiotis Zikos, Helen Papadaki, Despoina Mparmparousi, Eleni Bouronikou, Panayiotis Panayiotidis, Nora‐Athina Viniou, Vassiliki Pappa. The prognostic value of monosomal karyotype (MK) in higher‐risk patients with myelodysplastic syndromes treated with 5‐Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. American J Hematol 2018;93:895
    https://doi.org/10.1002/ajh.25111
  4. Haruya Okamoto, Yu Inoue, Akihiro Miyashita, Yuka Kawaji-Kanayama, Shotaro Chinen, Takahiro Fujino, Taku Tsukamoto, Yuji Shimura, Shinsuke Mizutani, Hiroto Kaneko, Saeko Kuwahara-Ota, Shin-ichi Fuchida, Daichi Nishiyama, Koichi Hirakawa, Hitoji Uchiyama, Nobuhiko Uoshima, Eri Kawata, Junya Kuroda. Real-world practice-based prognostic model for higher-risk myelodysplastic syndromes treated with azacitidine monotherapy: The Kyoto prognostic scoring system. Int J Hematol 2023;118:323
    https://doi.org/10.1007/s12185-023-03627-6
  5. Yanling Ren, Chen Mei, Li Ye, Yingwan Luo, Xinping Zhou, Haiyang Yang, Peipei Lin, Weilai Xu, Liya Ma, Jie Jin, Hongyan Tong. Analysis of clinical and molecular features of MDS patients with complex karyotype in China. Blood Cells, Molecules, and Diseases 2019;75:13
    https://doi.org/10.1016/j.bcmd.2018.11.006
  6. Na Wang, Hongzhi Xu, Qing Li, Jie Liu, Xiaohui Sui, Yujie Jiang, Xiaosheng Fang, Changqing Zhen, Mei Ding, Dai Yuan, Lingyan Zhang, Xin Wang. Monosomal karyotypes apart from complex karyotypes independently predict the outcome of myelodysplastic syndrome patients using a fluorescence in situ hybridization panel and conventional cytogenetics. Int J Lab Hematology 2019;41:519
    https://doi.org/10.1111/ijlh.13041
  7. Eva Hellström-Lindberg, Magnus Tobiasson, Peter Greenberg. Myelodysplastic syndromes: moving towards personalized management. haematol 2020;105:1765
    https://doi.org/10.3324/haematol.2020.248955
  8. Michael Lübbert, Stefan Suciu, Anne Hagemeijer, Björn Rüter, Uwe Platzbecker, Aristoteles Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Helmut R. Salih, Petra Muus, Karl-Heinz Pflüger, Hans-Eckart Schaefer, Lioudmila Bogatyreva, Carlo Aul, Theo de Witte, Arnold Ganser, Heiko Becker, Gerwin Huls, Lieke van der Helm, Edo Vellenga, Frédéric Baron, Jean-Pierre Marie, Pierre W. Wijermans. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann Hematol 2016;95:191
    https://doi.org/10.1007/s00277-015-2547-0
  9. Magnus Tobiasson, Donal P. McLornan, Mohsen Karimi, Marios Dimitriou, Monika Jansson, Asmaa Ben Azenkoud, Martin Jädersten, Greger Lindberg, Hani Abdulkadir, Austin Kulasekararaj, Johanna Ungerstedt, Andreas Lennartsson, Karl Ekwall, Ghulam J. Mufti, Eva Hellström-Lindberg. Mutations in histone modulators are associated with prolonged survival during azacitidine therapy. Oncotarget 2016;7:22103
    https://doi.org/10.18632/oncotarget.7899
  10. M. Tobiasson, A. O. Kittang. Treatment of myelodysplastic syndrome in the era of next‐generation sequencing. J Intern Med 2019;286:41
    https://doi.org/10.1111/joim.12893
  11. Panagiotis T. Diamantopoulos, Nora-Athina Viniou. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?. Leukemia Research 2021;103:106543
    https://doi.org/10.1016/j.leukres.2021.106543
  12. Anthi Bouchla, Thomas P Thomopoulos, Sotirios G Papageorgiou, Christina Apostolopoulou, Constantinos Loucari, Efthimia Mpazani, Vasiliki Pappa. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics 2021;13:1129
    https://doi.org/10.2217/epi-2021-0124
  13. Maria Teresa Voso, Francesco Lo-Coco, Luana Fianchi. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. 2015;27:532
    https://doi.org/10.1097/CCO.0000000000000231
  14. Yi-Cun Wu, Xiao-Mei Zhang, Yuan-Dong Zhu, Wei Wu. Prognostic significance of monosomal karyotype in myelodysplastic syndrome: a meta-analysis. Hematology 2019;24:60
    https://doi.org/10.1080/10245332.2018.1510067
  15. Brian C. Shaffer, Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, Ulrike Bacher, Betty Hamilton, Mohamed A. Kharfan-Dabaja, Ayman Saad, Corey Cutler, Erica Warlick, Ran Reshef, Baldeep Mona Wirk, Mitchell Sabloff, Omotayo Fasan, Aaron Gerds, David Marks, Richard Olsson, William Allen Wood, Luciano J. Costa, Alan M. Miller, Jorge Cortes, Andrew Daly, Tamila L. Kindwall-Keller, Rammurti Kamble, David A. Rizzieri, Jean-Yves Cahn, Robert Peter Gale, Basem William, Mark Litzow, Peter H. Wiernik, Jane Liesveld, Bipin N. Savani, Ravi Vij, Celalettin Ustun, Edward Copelan, Uday Popat, Matt Kalaycio, Richard Maziarz, Edwin Alyea, Ron Sobecks, Steven Pavletic, Martin Tallman, Wael Saber. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. JCO 2016;34:1864
    https://doi.org/10.1200/JCO.2015.65.0515
  16. Kamil Wiśniewski, Katarzyna Pruszczyk-Matusiak, Bartosz Puła, Ewa Lech-Marańda, Joanna Góra-Tybor. Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine—A Retrospective Analysis. Cancers 2024;16:1333
    https://doi.org/10.3390/cancers16071333
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd